Q3 2023

Filed Nov 14, 2023 · 10-Q · 45 days after period end · 0001493152-23-041032

Q3 2023 · 10-Q

Revenue

$0.00

— vs Q3 2022

Net Income

-$1.40M

N/M vs Q3 2022

EPS Diluted

-$0.32

N/M vs Q3 2022

Operating Income-$1,431,712N/M

Operating Cash Flow

Same quarter

Metric	Q3 2023	Q3 2022	Q3 2021	Q3 2020
Revenue	$0.00	$0.00	$0.00	$0.00
Net Income	-$1.40M	-$925.31K	-$878.30K	-$1.05M
EPS Diluted	-$0.32	-$0.21	-$0.05	-$0.10

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protagenic Therapeutics, Inc.\new · CIK 1022899 · Engraved from SEC EDGAR